Opens in a new tab

About

About

Immunic is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases.
doctor giving pills
About Us

Immunic Therapeutics

Immunic is developing a clinical pipeline of orally administered, small molecule therapies:

The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026. Initiation of an additional phase 3 clinical trial in progressive multiple sclerosis is ongoing, with first-patient-enrolled expected in the first half of 2027. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1, or Nurr1, activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase, or DHODH.

The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases.

Management

Board of Directors

Questions?

Get in touch.

Send an Email
Immunic, Inc. (Nasdaq: IMUX) Stock Quote:
Currency in USD. Quote data delayed at least 15 minutes.